Bourn, Jennifer
Rathore, Kusum
Donnell, Robert
White, Wesley
Uddin, Md. Jashim
Marnett, Lawrence
Cekanova, Maria https://orcid.org/0000-0002-9651-1619
Funding for this research was provided by:
National Cancer Institute (R15 CA182850-01A1)
University of Tennessee (R181721-351, E180121)
Article History
Received: 7 June 2019
Accepted: 15 November 2019
First Online: 27 November 2019
Ethics approval and consent to participate
: All animal experiments were performed in accordance with approved the University of Tennessee Institutional Animal Care and Use Committee (IACUC) protocol#1892 and in an accordance with all federal, and state guidelines, policies, and regulations to protect animal welfare. The University of Tennessee policies for animal care and use encompass regulations of the Animal Welfare Act as amended (Public Law 99–198 – The Improved Standard for Laboratory Animals Act), Guide for the Care and Use of Laboratory Animals (8th Ed.) and The Guide for the Care and Use of Agricultural Animals in Research and Teaching. The University of Tennessee IACUC is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).
: Not applicable.
: Authors from the University of Tennessee declare that they have no competing interest. Vanderbilt University holds a patent on fluorocoxibs and their use for COX-2-targeted imaging.